RVMD

Bullish

Revolution Medicines, Inc. announced that it will highlight the groundbreaking results from the Phase 3 Rasolute 302 pivotal clinical trial of Daraxonrasib in previously treated patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Revolution Medicines, Inc. is set to present breakthrough findings from its Phase 3 Rasolute 302 clinical trial of Daraxonrasib at the ASCO Annual Mee...

Bitget Yesterday 0

Neutral

Eagle Health Investments LP Makes New $9.23 Million Investment in Revolution Medicines, Inc. $RVMD

Eagle Health Investments LP has made a new $9.23 million investment in Revolution Medicines, Inc. (NASDAQ:RVMD), acquiring 115,900 shares and making i...

MarketBeat 1 week ago 0

Neutral

FDA Expanded Access Puts Revolution Medicines Daraxonrasib Thesis To The Test

The FDA has granted expanded access to Revolution Medicines' RAS(ON) inhibitor daraxonrasib for metastatic pancreatic cancer, prior to formal approval...

Simply Wall Street 4 weeks ago 0